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SUMMARY
Objectives: The epilepsy treatment gap is large in low- and middle-income countries,
but the reasons behind nonadherence to treatment with antiepileptic drugs (AEDs)
across African countries remain unclear. We investigated the extent to which AEDs
are not taken and associated factors in people with active convulsive epilepsy (ACE)
identified in cross-sectional studies conducted in five African countries.
Methods: We approached 2,192 people with a confirmed diagnosis of ACE for consent
to give blood voluntarily. Participants were asked if theywere takingAEDs, and plasma
drug concentrations were measured using a fluorescence polarization immunoassay
analyzer. Information about possible risk factors was collected using questionnaire-
based clinical interviews. We determined factors associated with nonadherence to
AED treatment in children and adults, as measured by detectable and optimal levels,
usingmultilevel logistic regression.
Results: In 1,303 samples assayed (43.7% were children), AEDs were detected in 482,
but only 287 had optimal levels. Of the 1,303 samples, 532 (40.8%) were from people
who had reported they were on AEDs. The overall prevalence of nonadherence to
treatment was 63.1% (95% confidence interval [CI] 60.5–65.6%) as measured by
detectable AED levels and 79.1% (95% CI 73.3–84.3%) as measured by optimal AED
levels; self-reported nonadherence was 65.1% (95% CI 45.0–79.5%). Nonadherence was
significantly (p < 0.001) more common among the children than among adults for
optimal and detectable levels of AEDs, as was the self-reported nonadherence. In chil-
dren, lack of previous hospitalization and learning difficulties were independently
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associated with nonadherence to treatment. In adults, history of delivery at home,
absence of burnmarks, and not seeking traditional medicine were independently asso-
ciated with the nonadherence toAED treatment.
Significance: Only about 20% of people with epilepsy benefit fully from antiepileptic
drugs in sub-Saharan Africa, according to optimumAEDs levels. Children taking AEDs
should be supervised to promote compliance.
KEY WORDS: Antiepileptic drugs, Adherence, sub-Saharan Africa, Epilepsy, Treat-
ment gap.
Epilepsy is ubiquitous but appears to be more prevalent in
resource-poor settings.1 It is associated with morbidity and
premature mortality,2 and it exerts a considerable burden on
health systems, especially in low-income countries.3 People
with epilepsy have poor social and health outcomes.4,5 They
may also have behavioral problems,4 learning difficulties,
and neurological deficits and may frequently be burned.5
They are often stigmatized, which is associated with lower
socioeconomic status, poor marriage prospects,5 and poor
performance in those attending school.6
Epileptic seizures can be successfully controlled in up to
70% of people using relatively inexpensive antiepileptic
drugs (AEDs).7 Most people with epilepsy in Africa,8 how-
ever, do not seek biomedical treatment. Additionally, many
of those who are prescribed treatment do not adhere to it,
which contributes to the epilepsy treatment gap, hereafter
referred to as nonadherence to AED treatment or as nontak-
ing of AEDs8,9 and defined as the proportion of people with
active epilepsy whose seizures are not treated appropriately
expressed as a percentage.10 There is some evidence that
premature mortality is lower and disability-adjusted life
years fewer in those taking AEDs regularly.2,11 The extent
of nonadherence and associated factors are not fully under-
stood in Africa, probably because of lack of facilities to
measure AED levels.
Two studies in Kenya measured nonadherence on the
basis of either self-reports or blood levels, with the latter
determined from detectable or optimal levels of AEDs.12,13
The findings of these studies cannot be generalized to other
African settings, where causes and beliefs about epilepsy
may differ.14 Self-reported nonadherence is easy, inexpen-
sive, and convenient to measure, but it is an insensitive mea-
sure with poor specificity compared to nonadherence
measured by blood levels.13,15 It is important to validate the
self-reported nonadherence against AED levels from other
settings in Africa. Little is known about the factors associ-
ated with nontaking as measured by optimal levels, espe-
cially in sub-Saharan Africa.
We assessed the magnitude of nonadherence as measured
by AED levels in people with active convulsive epilepsy
(ACE) from five sites in Africa. We also investigated factors
associated with optimal drug levels. We hypothesized that
nonadherence prevalence and associated factors will differ
according to site because there may be cultural, economic,
and health-seeking behavior differences across the sites.
Methods
Study setting
This study was nested within large population-based
cross-sectional studies in five Health and Demographic
Surveillance Systems (HDSSs), which are part of the Inter-
national Network for the Demographic Evaluation of Popu-
lations and Their Health (INDEPTH) (http://www.indepth-
network.org/). These studies employed a three-stage screen-
ing methodology to identify people with ACE in Kilifi,
Kenya (lower-middle-income country); Agincourt, South
Africa (upper-middle-income country); Iganga-Mayuge,
Uganda (low-income country); Ifakara, Tanzania (low-
income country), and Kintampo in Ghana (lower-middle-
income country) (databank.worldbank.org/data/download/
site-content/CLASS.xls).16,17
Briefly, Kilifi HDSS is located in a rural area on the Ken-
yan coast, has a population of about 280,000 in an area of
891 km2, and hosts studies of childhood infections and neu-
rological/mental health disorders. Agincourt HDSS is
located in a semiarid area on the northeast of South Africa,
covers 420 km2, has a population of 82,795, and has a mor-
tality rate of 22/1,000. Iganga-Mayuge HDSS is located
near the shores of Lake Victoria, with a population of about
64,143, and hosts studies on neonatal and childhood infec-
tions. Ifakara HDSS is located in rural southern Tanzania,
with a population of 93,423, and hosts studies on childhood
Key Points
• Only about 20% of persons with epilepsy in Africa
benefit fully from antiepileptic drugs (AEDs)
• Nonadherence was greater in children than in adults
• The reasons for the significantly higher rate of nonad-
herence to AEDs found in children compared to adults
are unclear
• Status epilepticus was more common in children,
which may be a consequence of poor seizure control
owing to nonadherence in children
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infections and maternal/child health. Kintampo HDSS is
located in central Ghana, in an area of 3,162 km2, has a
mortality rate of 7.8/1,000, and conducts studies on mental
health problems.5,17
Study participants and procedures
The study population consisted of people with a
confirmed diagnosis of ACE who were identified from com-
munity cross-sectional surveys conducted between August
2008 and April 2011 (1,711 people)17 and those who had
earlier concealed their epilepsy status in the surveys but
later presented to epilepsy clinics within the study sites
during the study period (481 people).5 Phenobarbital,
phenytoin, carbamazepine, and sodium valproate are the
AEDs most commonly available in main public and private
hospitals and pharmacies, although the supply may be erra-
tic. A total of 2,192 people were visited in their homes by a
trained fieldworker and asked to consent to participate.
Those who consented were invited to their local assessment
centers, where data on possible risk factors was collected
through interview-based questionnaires on sociodemo-
graphic and clinical characteristics. The parent or caregiver
was interviewed if the person with epilepsy was a child or
cognitively impaired. Blood samples were taken from the
participants following an informed consent. ACE was
defined as the presence of at least two unprovoked convul-
sive seizures, with at least one seizure within the previous
12 months, which are the criteria for starting AED treat-
ment in many parts of Africa.17 Focal seizures were defined
as those involving one part of the body; frequent seizures as
those occurring daily; and status epilepticus as seizures
lasting for at least 30 min.5,18,19
People were asked if they were taking AEDs (with tablets
of the different AEDs shown on a board), which was defined
as self-reported adherence. The self-reported nonadherence
was calculated as the proportion of those diagnosed with
epilepsy who said they were not on medication. Blood sam-
ples were assayed for the most commonly used AEDs at the
five sites (phenobarbital, phenytoin, carbamazepine, and
sodium valproate) on basis of the AEDs that are prescribed
at each site (sodium valproate was only assayed for the
South African site). At each site, blood was collected in
4-ml heparin tubes and placed in racks sealed in plastic
bags. The racks with the blood tubes were placed in secured
transport boxes with cool packs and then were transported
to the site laboratory within 6 h and stored in 80°C freez-
ers. The transport boxes were then collected by a courier at
an agreed upon time for transportation to Kilifi. Plasma drug
concentrations were measured using a fluorescence polar-
ization immunoassay analyzer (TDxFLx Abbott Laborato-
ries, Abbott Park, IL, U.S.A.). For standardization, all
assays were done at one site (Kilifi, Kenya). Nonadherence
was calculated as the proportion of those diagnosed with
epilepsy but not on appropriate biomedical treatment for
seizures—either they do not seek biomedical treatment or
do not adhere to the prescribed regimes—expressed as a
percentage.8–10 The detectable ranges for the different drugs
were classified as follows: phenobarbital 1.1 lg/ml, pheny-
toin 1.0 lg/ml, carbamazepine 0.5 lg/ml, and sodium val-
proate 1.0 lg/ml. The optimal ranges were: phenobarbital
10–40 lg/ml, phenytoin 10–20 lg/ml, carbamazepine
4–11 lg/ml, and sodium valproate 50–120 lg/ml.13,15,20
Nonadherence, as measured by detectable and optimal AED
levels, was calculated as the proportion of those diagnosed
with epilepsy who had lower than detectable levels to those
who had optimal levels of AEDs. The sensitivity of self-
reported nonadherence was computed as the proportion of
those without detectable AED levels who reported to the
clinician that they did not take AEDs during the clinical his-
tory stage, and the speciﬁcity was computed as the propor-
tion of those with detectable AED levels who reported taking
them.
Because the magnitude of nonadherence from Kilifi has
been previously published,13 we used AED level data from
this site together with similar data from other sites to deter-
mine the overall extent of nonadherence, to compare the
site-specific nonadherence measures, and to investigate the
factors associated with not taking the AEDs across all the
five sites. In Kilifi only factors associated with detectable
but not optimal levels of AEDs have been reported previ-
ously,12,13 so we measured associations for optimal levels
for all the five sites. We investigated factors (Table S1)
associated with nonadherence across the sites to determine
whether similar interventions would help improve taking of
AEDs. The investigated factors in Table S1, including
burns, previous hospitalization, and learning difficulties
were obtained through standard questionnaire-based inter-
views or clinical examinations performed by trained epi-
lepsy clinicians. The prevalence of nonadherence in Kilifi
was 62.4% for detectable levels of AEDs and 81.6% for
optimal drug levels, while the self-reported adherence was
73.7%.13
Statistical analysis
The data were double entered and verified in MySQL
Version 5 open-source database (Oracle Corporation, Red-
wood Shores, CA, U.S.A.). All analyses were performed
using R, an open-source software for statistical computing
and graphics (version 3.1.2).21 The Pearson chi-square test
or (Fisher’s exact test where appropriate) was used to exam-
ine the distribution of participants’ characteristics across the
five sites. The Wilcoxon rank-sum test was used to compare
the median ages of the participants across the five sites.
Nonadherence to treatment was defined as the proportion of
people with epilepsy (PWE) not on appropriate AEDs based
on self-reports, detectable AED levels, or optimal AED
levels. The overall prevalence of nonadherence (as mea-
sured by AEDs detectable in plasma and from self-reports)
was modeled using multilevel logistic regression because
this accounts for potential clustering within the sites (the site
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was taken as the second level in the multilevel model),
which could result in underestimation of standard errors in
model coefficients. The degree of heterogeneity of adher-
ence from PWE from the same site was computed using the
intraclass correlation coefficient (ICC).22 To obtain the non-
adherence estimate from the model, we applied the inverse
of link function. The multilevel models were fitted using the
lme4 package in R, and the arm package23 was used to com-
pute the confidence intervals.24
Multilevel logistic regression (with site as the second
level) was used to investigate the factors (that could be reli-
ably recorded in all sites) associated with nonadherence
based on optimal AEDs levels (Table S1). For each predic-
tor, a univariable model was fitted initially to identify vari-
ables for a multivariable multilevel model aimed at
ascertaining variables that were independently associated
with nonadherence. Only variables with p values < 0.25
were included in the multivariable models. We examined
whether the nonadherence was influenced by the differences
in the included explanatory variable across the sites using
the likelihood ratio test.22 Results from the models that fit
the data better across the sites were reported. Variables that
met criteria for inclusion into the multivariable model
(p < 0.25) were further investigated. The odds ratios (ORs)
and their corresponding 95% confidence intervals (95%
CIs) are reported. These analyses were done separately for
children (<18 years) and adults (≥18 years) because AED
use is thought to be different between the two groups.3 A p
value ≤ 0.05 is considered significant.
Ethical approval
This study was approved by the local institutional ethical
committees from the five sites and by the ethics committee
at the Institute of Child Health, University College London,
United Kingdom. Written informed consent was obtained
for each participant.
Results
Characteristics of the participants
Of the 2,192 who had been diagnosed with ACE, 1,303
(59.4%) consented and provided a blood sample. There
were no significant differences between those who provided
blood and those who did not apart from an overrepresenta-
tion of people without neurological deficits and those with
focal seizures in those who gave blood (Table S2), likely to
be those with ACE perceived as less severe. There was
equal representation of men and women (672 vs. 631,
p = 0.52; Table S2), but many other sociodemographic and
clinical factors from across the sites differed in children and
adults (Tables S3 and S4).
Antiepileptic drugs assayed
The samples were assayed for phenobarbital (1,145/
1,303, 87.9%), carbamazepine (313/1,303, 24.0%),
phenytoin (191/1,303, 14.7%), and sodium valproate (15/
1,303, 1.2%). Overall, 532/1,303 (41.0%) people with ACE
reported using AEDs: 397 of the 532 (74.6%) ever recalled
using phenobarbital; 146 (27.4%), carbamazepine, 118
(22.2%), phenytoin; 12 (2.3%), diazepam; and 78 (14.7%),
sodium valproate. AEDs were detected in 339/532 (63.7%),
with 253/339 (74.6%) on monotherapy. Table S5 shows the
distribution of detected AEDs compared to those reported.
AEDs were detected in 143 (18.5%) of those who said they
were not on medication.
Sensitivity and specificity of self-reported nonadherence
The sensitivity of the self-reported nonadherence as mea-
sured against detectable blood levels of AEDs for all sites
together was 76.5% (95% CI 73.4–79.4%) and the speci-
ficity was 70.3% (95% CI 66.0–74.4%). Sensitivity was
highest in Kintampo 91.1% (85.8–94.9%) and lowest in
Agincourt 58.0% (95% CI 47.7–67.8%) (Table 1). Speci-
ficity varied across the sites, being highest in Kilifi 94.7%
(95% CI 90.5–97.4%) and lowest in Kintampo 18.4% (95%
CI 11.3–27.5%).
Magnitude of nonadherence
The overall prevalence of nonadherence across the five
sites was 63.1% (95% CI 60.5–65.6%), as measured by
detectable AEDs levels, and 79.1% (95% CI 73.3–84.3%),
by optimal AEDs levels; self-reported nontaking of AEDs
was 65.1% (95% CI 45.0–79.5%) (Table 1). The prevalence
of nonadherence based on optimal AED levels was 84.9%
(95% CI 81.7–87.7%) for children and 73.8% (95% CI
70.4–76.9%) for adults. Additional age-group-specific non-
adherence estimates are summarized in Figs. S1 and S2.
Heterogeneity of nonadherence
There was considerable heterogeneity in the site-specific
nontaking of AEDs estimates based on optimal levels
(ICC = 3.3%) across the five sites and non-taking of AEDs
estimates from self-reports (ICC = 18.3%) (Fig. S1). Esti-
mates derived from the direct measurements of nontaking of
AEDs from the drug levels were more homogeneous, partic-
ularly based on detectable levels (ICC = 0%). We found
statistically significant differences in nontaking of AEDs
estimates among the five sites as measured by optimal levels
of AEDs, with the highest nonadherence (90.3%) recorded
in Iganga-Maguye and the lowest (72.7%) in Ifakara
(Table 1).
Relationship of age with nonadherence
We found that nontaking of AEDs (based on self-reports
and detectable and optimal levels of AEDs) decreased with
age, being smallest in those aged 18–28 years (Fig. S2).
Univariable association showed that children (<18 years
old) had significantly higher nontaking of AEDs estimates
than adults as measured by detectable (OR = 1.60, 95% CI
1.28–2.00, p < 0.001) and optimal AEDs levels
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(OR = 1.96, 95% CI 1.44–2.55, p < 0.001) and by the self-
reported nontaking (OR = 2.00, 95% CI 1.56–2.53,
p < 0.001).
Factors that differed between children and adults with
suboptimal AEDs
Among those without optimal AED levels, fewer children
were found to have burn marks (OR = 0.41, 95% CI 0.28–
0.63, p < 0.001) and learning difficulties (OR = 0.63, 95%
CI 0.44–0.89, p = 0.009) than adults. More children than
adults had a history of status epilepticus (OR = 1.98, 95%
CI 1.40–2.88, p < 0.001) (Table S6).
Factors associated with nonadherence in children
Several factors were investigated for an association with
nontaking of AEDs as measured from the optimal levels in
the univariable multilevel logistic regression model
(Table 2). From the likelihood ratio test, there was no evi-
dence that the investigated variables influenced nontaking
of AEDs differently across the five sites (all p values were >
0.05).
The four variables that had a univariable p value ≤0.25
(age, mother’s age at first birth, previous hospitalization,
and learning difficulties) were used to build a multivariable
model. Nontaking of AEDs was independently associated
with history of previous hospitalization (OR = 0.50, 95%
CI 0.28–0.87) and presence of learning difficulties
(OR = 0.51, 95% CI 0.26–0.97) (Table 3).
Factors associated with nonadherence in adults
Several factors were investigated for an association with
nontaking of AEDs as measured from the optimal levels in
the univariable multilevel logistic regression model
(Table 4). From the likelihood ratio test, there was also no
evidence that the variables under consideration influence
the nontaking of AEDs differently across the sites (all p val-
ues were > 0.05).
Eight factors (Table 4) with univariable p values ≤ 0.25
were used to build a multivariable model. Out of these fac-
tors, being born at home (OR = 2.06, 95% CI 1.21–3.61),
presence of burn marks (OR = 0.53, 95% CI 0.29–0.96),
and seeking traditional medicine (OR = 0.37, 95% CI 0.18–
0.79), were independently associated with the nontaking of
AEDs based on optimal levels (Table 3).
Discussion
We estimated the prevalence of nonadherence at 63% on
the basis of detectable AED levels and 79% on the basis of
optimum levels across five rural sites in Africa. Nonadher-
ence as measured by AED levels was more homogeneous
across the sites than self-reported nonadherence, suggesting
that AED levels detectable in blood are more reliable. Also,
social desirability bias (a response bias in which respon-
dents tend to give responses that are favorable or acceptable
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Table 2. Univariable analysis of factors associated with nonadherence to antiepileptic drugs in childrena
Factors
Adhering to medication
n = 86
Not adhering to medication
n = 484 Odds ratio (95%CI) p value
Age (years): median (IQR) 12.0 (8.25–14.23) 11.0 (7.0–14.9) 0.97 (0.92–1.01) 0.20
Sex
Male 43 (50.0%) 222 (45.9%) 0.85 (0.52–1.38) 0.48
Mother’s religious affiliation
Christianity 52 (69.3%) 278 (67.0%) 1
Islam 16 (21.3%) 110 (26.5%) 1.29 (0.69–2.52) 0.41
Traditionalist 7 (9.3%) 27 (6.5%) 0.72 (0.29–2.07) 0.47
Mother’s marital status
Married 65 (75.6%) 375 (77.5%) 1
Single/separated/divorced/widowed 21 (24.4%) 109 (22.5%) 0.90 (0.52–1.62) 0.70
Mother’s education level
Postprimary 6 (16.2%) 47 (21.1%) 1
≤Primary school 31 (83.8%) 176 (78.9%) 0.70 (0.23–1.91) 0.50
Mother’s occupation
Employed 5(10.9%) 33 (12.8%) 1
Unemployed 41 (89.1%) 224 (87.2%) 0.83 (0.24–2.31) 0.71
Father’s education level
Postprimary 14 (29.2%) 77 (28.8%) 1
≤Primary school level 34 (70.8%) 190 (71.2%) 1.02 (0.48–2.07) 0.96
Father’s occupation
Employed 12 (27.3%) 86 (29.0%) 1
Unemployed 32 (72.7%) 211 (71.0%) 0.92 (0.41–1.94) 0.82
Mother’s age at first birth
≥18 years 38 (65.5%) 201 (57.4%) 1
<18 years 20 (34.5%) 149 (42.6%) 1.41 (0.76–2.66) 0.25
Sibling has seizures
No 12 (14.0%) 52 (10.7%) 1
Yes 74 (86.0%) 432 (89.3%) 1.35 (0.62–2.71) 0.39
Snores more than 3 days per week
No 36 (45.0%) 206 (44.0%) 1
Yes 44 (55.0%) 262 (56.0%) 1.04 (0.63–1.72) 0.87
Place of birth: home
No 30 (35.3%) 174 (36.4%) 1
Yes 55 (64.7%) 304 (63.6%) 0.95 (0.57–1.58) 0.84
Burn marks
No 73 (85.9%) 436 (90.1%) 1
Yes 12 (14.1%) 48 (9.9%) 0.67 (0.33–1.45) 0.24
Sought traditional medicine
No 21(26.9%) 140 (31.7%) 1
Yes 57(73.1%) 302 (68.3%) 0.79 (0.44–1.39) 0.40
Previous hospitalization
No 34 (40.0) 267 (55.5%) 1
Yes 51(60.0%) 214 (44.5%) 0.53 (0.32–0.88) 0.008
Learning difficulties
No 59 (69.4%) 402 (83.1%) 1
Yes 26 (30.6%) 82 (16.9%) 0.46 (0.27>–0.81) 0.003
Neurological deficits
No 74 (87.1%) 410 (86.8%) 1
Yes 11 (12.9%) 64 (13.2%) 1.05 (0.52–2.31) 0.89
Frequent seizures
No 70 (81.4%) 416 (86.1%) 1
Yes 16 (18.6%) 67 (13.9%) 0.70 (0.38–1.38) 0.25
Focal seizures
No 43 (50.0%) 259 (53.5%) 1
Yes 43 (50.0%) 225 (46.5%) 0.87 (0.53–1.41) 0.55
Status epilepticus
No 59 (73.8%) 304 (68.6%) 1
Yes 21 (26.2%) 139 (31.4%) 1.28 (0.73–2.32) 0.36
CI, confidence interval; IQR, interquartile range.
aNonadherence to antiepileptic drugs was evaluated on the basis of optimal drug levels in the blood.
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by others) linked to stigma may prompt persons with epi-
lepsy in Africa not to disclose their nonadherence to AEDs.
The differences observed in nonadherence determined by
optimal levels may be explained by differences in specific
AEDs prescribed at the sites whose pharmacokinetics and
pharmacodynamics differ, although heterogeneity owing to
other site-specific factors cannot be excluded. Estimates for
nonadherence were significantly greater in children.
Sensitivity and specificity
The sensitivity and specificity of the self-reported nonad-
herence compared to detectable levels varied with sites. In
Kilifi, the sensitivity and specificity of self-reporting (mea-
sured with the Morisky scale [a four-item questionnaire])
compared to detectable levels were lower than those
reported in this study, where self-reported nonadherence
was based on one question.13 This suggests that the Morisky
scale is stringent and that one-item self-reported adherence
is a better correlate of detectable AEDs levels. In fact, non-
adherence from self-report and that from detectable levels
were comparable. The sensitivity and specificity, however,
varied across the sites, with some sites registering low
Table 3. Multivariable analysis for factors associated
with nonadherence to antiepileptic drugs asmeasured by
optimal levels in the blood of children and adults
Odds ratio (95%CI) p value
Children
Age (years) 0.90 (0.96–1.02) 0.17
Mother’s age at first birth 1.35 (0.74–2.44) 0.35
Previous hospitalization
No 1
Yes 0.50 (0.28–0.87) 0.02
Learning difficulties
No 1
Yes 0.51 (0.26–0.97) 0.04
Adults
Age (years) 1.00 (0.98–1.02) 0.88
Marital status
Married 1
Single/separated/divorced/
widowed
0.84 (0.44–1.60) 0.59
Level of education
Postprimary 1
≤Primary school 1.48 (0.88–2.56) 0.14
Place of birth: home
No 1
Yes 2.06 (1.21–3.61) 0.01
Snores more than three times
per week
No 1
Yes 0.76 (0.44–1.24) 0.26
Burn marks
No 1
Yes 0.53 (0.29–0.96) 0.04
Sought traditional medicine
No 1
Yes 0.37 (0.18–0.79) 0.006
Previous hospitalization
No 1
Yes 0.84 (0.48–1.38) 0.48
Learning difficulties
No 1
Yes 0.88 (0.52–1.65) 0.71
CI, confidence interval.
Table 4. Univariable analysis for factors associated with
nonadherence to antiepileptic drugs in adultsa
Factors
Adhering to
medication
n = 192
Not adhering
to medication
n = 541
Odds ratio
(95% CI) p value
Age (years):
median (IQR)
27.8 (22.9–38.0) 29.5 (23.0–41.0) 1.01 (0.99–1.02) 0.14
Sex: Female 95 (49.5%) 272 (50.3%) 1.03 (0.73–1.46) 0.85
Religion
Christianity 118 (75.2%) 322 (75.2%) 1
Islam 25 (15.9%) 70(16.4%) 1.02 (0.61–1.77) 0.92
Traditionalist 14 (8.9%) 36 (8.4%) 0.94 (0.48–1.96) 0.85
Marital status
Married 50 (26.5%) 172 (33.5%) 1
Single/separated/
divorced/widowed
136 (73.5%) 341 (66.5%) 0.73 (0.49–1.07) 0.09
Level of education
Postprimary 46 (42.2%) 105 (35.4%) 1
≤Primary school 63 (57.8%) 192 (64.6%) 1.34 (0.83–2.14) 0.21
Occupation
Employed 6 (8.6%) 14 (7.9%) 1
Unemployed 64 (91.4%) 163 (92.1%) 1.09 (0.33–3.19) 0.86
Sibling has seizures
No 166 (86.5%) 484 (89.5%) 1
Yes 26 (13.5%) 57 (10.5%) 0.75 (0.45–1.29) 0.26
Snores more than
three days per week
No 75 (39.9%) 245 (48.7%) 1
Yes 113 (60.1%) 258 (51.3%) 0.70 (0.49–0.99) 0.04
Place of birth: home
No 62 (33.7%) 134 (25.7%) 1
Yes 122 (66.3%) 388 (74.3%) 1.47 (1.00–2.15) 0.04
Burn marks
No 134 (69.8%) 421 (78.1%) 1
Yes 58 (30.2%) 118 (21.9%) 0.65 (0.44–0.96) 0.02
Sought traditional
medicine
No 27 (15.1%) 117 (23.3%) 1
Yes 152 (84.9%) 385 (76.7%) 0.58 (0.35–0.94) 0.02
Previous
hospitalization
No 104 (54.2%) 320 (59.7%) 1
Yes 88 (45.8%) 216 (40.3%) 0.80 (0.56–1.13) 0.18
Learning difficulties
No 135 (70.3%) 400 (74.3%) 1
Yes 57 (29.7%) 138 (25.7%) 0.82 (0.56–1.20) 0.28
Neurological deficits
No 167 (87.0%) 462 (85.7%) 1
Yes 25 (13.0%) 77 (14.3%) 1.11 (0.67–1.89) 0.66
Frequent seizures
No 175 (91.1%) 480 (88.7%) 1
Yes 17 (8.9%) 61 (11.3%) 1.31 (0.73–2.46) 0.35
Focal seizures
No 96 (50.0%) 269 (49.7%) 1
Yes 96 (50.0%) 272 (50.3%) 1.01 (0.72–1.42) 0.95
Status epilepticus
No 148 (84.1%) 393 (80.2%) 1
Yes 28 (15.9%) 97 (19.8%) 1.36 (0.84–2.26) 0.26
CI, confidence interval; IQR, interquartile range.
aNonadherence to antiepileptic drugs as evaluated on the basis of optimal
drug levels in the blood.
Epilepsia Open, 2(2):226–235, 2017
doi: 10.1002/epi4.12052
232
F. Ibinda et al.
values, suggesting that self-reported nontaking is unreliable
and can be influenced by different factors within each site.
Magnitude of nonadherence
Estimates of nonadherence as measured by detectable
levels (63%) and by self-reports documented in this study
are similar to those previously reported in Kenyan studies
and in a recent systematic review.1,13,15 Overall nonadher-
ence is in line with the results of a recent review, which esti-
mated nonadherence for detectable levels at 59% (95% CI
32–85%).25 Nonadherence estimates as measured by opti-
mum drug levels, however, were greater (79%), probably
because these measures were based on higher cut-off AED
levels that are clinically beneficial. These findings highlight
nonadherence as a widespread problem in sub-Saharan
Africa, and this in part explains the large treatment gap in
Africa. It is likely that some common causes of nonadher-
ence do exist in these countries and could include cost of
AEDs, distance to health facilities, and cultural beliefs
about epilepsy and treatment.8,14 Some of these specific
causes were not investigated in this study, and future studies
at each site are warranted.
There was heterogeneity in rates of nonadherence to
AEDs as measured from blood levels and self-reports,
although it was significantly greater in the latter than in the
former. Heterogeneity in observed nonadherence may be
related to the social desirability bias and epilepsy stigma
(for self-reported nonadherence) and methodological differ-
ences (for nonadherence measured by blood levels). We,
however, attempted to use standardized questionnaires and
procedures for blood collection and transportation to mini-
mize heterogeneity.
Nonadherence and its association with age
We found that nonadherence is greater in children, as in
previous reports.13,15 The reasons for this are not yet clear
but may be related to health-seeking behaviors or less severe
epilepsy, as suggested by the presence of burn marks
(though not statistically significant) and history of previous
hospitalization for any condition, including febrile illnesses.
Epilepsy may be perceived as severe and requiring prompt
treatment if it is associated with burn marks or learning dis-
ability, particularly in children.5 Previous hospitalization is
associated with AED taking, probably because it suggests
positive health-seeking behavior or was documented in
those living near hospitals.3
The high nonadherence estimates in children could also
be attributed to the fact that collection and taking of medica-
tion depend on adults, who may fail to seek treatment for
their children, possibly owing to cultural beliefs.25 Further-
more parents may think that their child has acute febrile
seizures, which are not considered serious, and therefore
they are not motivated to seek treatment for their child.26
Differences in pharmacokinetics of drugs in these two
groups—children usually have faster drug elimination rates
and reduced blood half-lives compared to adults—may
affect our estimates.27 A titration schedule that ensures a
maximum tolerated dose should be explored to ensure opti-
mum levels for seizure control in children.27 Bimodal age-
related incidence peak of status epilepticus is present in the
very young and very old in populations; thus, the low non-
adherence in children with status epilepticus could suggest
this is a biological phenomenon and not the result of AED
adherence. Whatever the reason, the large nonadherence
estimates in African children need to be addressed because
(1) most complications, including those that are potentially
fatal such as convulsive status epilepticus, were more com-
mon in this group;18,28 and (2) children with epilepsy have a
poor quality of life, which could hinder them from attaining
full developmental potential, making this group of special
clinical importance.29,30
Factors associated with nonadherence to treatment
Nonadherence was associated with history of previous
hospitalization in children, a factor that may be a surrogate
marker of health-seeking behavior or distance to health
facilities.3 In a recent Kenyan study, previous hospitaliza-
tion was independently associated with admission to hospi-
tal for epilepsy, suggesting that distance influences the
decision to seek biomedical treatment for epilepsy in this
area.3 Alternatively, those without previous hospitalization
may be people who do prefer not to access biomedical ser-
vices, thereby the association with nonadherence.
In adults, nonadherence was associated with being born
at home, which could suggest negative attitudes toward use
of biomedical facilities. This is supported by the association
between seeking traditional treatment and taking of AEDs,
whereby people who visit traditional healers are now likely
to go to the hospital following educational interventions in
this area.15 The association between traditional medicine
use and the taking of AEDs is interesting and should be
interpreted in the contexts of two groups of people with epi-
lepsy. The first group exclusively prefers traditional medi-
cine to biomedical treatment and would not resort to the
latter even when the former fails, thereby contributing to the
large treatment gap for epilepsy. The second group uses
both traditional and biomedical treatments, in either order
and concurrently, and may therefore appear to be adhering
to antiepileptic drugs, as supported by results from this mul-
tisite study. This study found a strong association between
presence of burn marks and the taking of AEDs. Burns are
often caused by accidents during seizures and may prompt
individuals to seek biomedical treatment for their
epilepsy.13
Strengths and limitations
We used a standard methodology to identify people with
epilepsy and to determine nonadherence estimates across
five sites.5,17 We also used a robust statistical approach that
accounted for possible clustering within the sites. The
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sample size was large enough to allow for adequate power
to measure differences between groups. The limitation is
that we were not able to investigate known causes of nonad-
herence in all sites identified from other studies. The other
limitation is the selection bias with overrepresentation of
people with focal seizures (Table S2), which may be due to
epilepsy stigma or misperception of epilepsy as less
severe.31 Only active convulsive epilepsy was included in
the study, and nonadherence may be different in those with
inactive epilepsy and nonconvulsive epilepsy not in the
study. Additionally, the assigned daily dose was unknown,
and we could only speculate that the patient received (and
took) a correct dose at the discretion of the caring physician.
Conclusion
Many people with epilepsy in Africa do not take AEDs
(about 80%, based on optimum levels), and this nonadher-
ence is worse in children, in whom dosing schedules should
be closely monitored by clinicians to ensure maximum tol-
erated and effective doses and AED taking should be super-
vised by parents. The reasons for the significantly higher
nonadherence estimates found in children compared with
adults warrant further studies in sub-Saharan Africa. The
high rate of nontaking of AEDs in children needs to be
addressed because most complications such as convulsive
status epilepticus were found to be more common in this
group and are associated with significant mortality and neu-
rological damage. Untreated epilepsy can hinder children
from attaining their full developmental and societal
potential.
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